tiprankstipranks
Trending News
More News >

QIAGEN N.V. Files 2024 Annual Report with SEC

Story Highlights
QIAGEN N.V. Files 2024 Annual Report with SEC

Qiagen ( (QGEN) ) just unveiled an update.

QIAGEN N.V. has announced the filing of its Form 20-F Annual Report for the fiscal year ending December 31, 2024, with the United States Securities and Exchange Commission (SEC). This filing is a regulatory requirement and provides stakeholders with detailed information about the company’s financial performance and operations, which is now accessible on QIAGEN’s website.

More about Qiagen

QIAGEN N.V. operates in the biotechnology industry, focusing on providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its products and services that enable customers to gain valuable insights from biological samples.

YTD Price Performance: -10.50%

Average Trading Volume: 1,193,839

Technical Sentiment Signal: Strong Buy

Current Market Cap: $8.67B

For an in-depth examination of QGEN stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App